Last reviewed · How we verify
NCT05109455: MANOTRAS
Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.
Phase 4 trial testing MANOSAR® in Kidney Transplant Infection in 60 participants. Completed in 17 February 2023.
25 March 2021
Quick facts
| Lead sponsor | Arafarma Group, S.A. |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 16 April 2019 |
| Primary completion | 25 March 2021 |
| Estimated completion | 17 February 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- MANOSAR®
- Proanthocyanidins
Conditions studied
- Kidney Transplant Infection — all drugs for Kidney Transplant Infection →
Sponsor
Arafarma Group, S.A. — full company profile →
Who can join
18 and older, any sex, with Kidney Transplant Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of Urinary tract infections (UTIs) is very high in kidney transplant patients. Most UTIs occur during the first six months (82% within the first three months) of kidney transplantation and are frequently recurrent. The component D-mannose of our authorized food supplement acts by inhibiting the adherence of E.coli to the urothelium. It also has a controlled release formula that ensures the presence in urine of D-mannose and the other components during 24 hours. This is the reason why this experimental study aims to demonstrate that the oral intake of this food supplement is effective in the prevention of UTIs in kidney transplant patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05109455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Infection
Currently open trials in the same condition.
- NCT05597540 — Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Mult · Phase 3 · recruiting
- NCT05708534 — Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept. · recruiting
- NCT05325008 — A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients · Phase 3 · recruiting
- NCT05836636 — Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort · active not recruiting
- NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
Other Arafarma Group, S.A. trials
Trials by the same sponsor.
- NCT07393958 — Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain. · NA · recruiting
- NCT07199556 — Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors. · NA · completed
- NCT05718908 — Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement · completed
- NCT05525130 — Study of the Administration of a Food Supplement in Patients With Lithiasis Treated With Extracorporeal Shock Wave Litho · NA · completed
- NCT04815499 — Effects of a Food Supplement on Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05109455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arafarma Group, S.A.
- Last refreshed: 24 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing